Halozyme Therapeutics Inc. (HALO) Stock Price Down 2.8%
Halozyme Therapeutics Inc. (NASDAQ:HALO) fell 2.8% during mid-day trading on Tuesday . The stock traded as low as $10.00 and last traded at $10.01, with a volume of 713,997 shares changing hands. The stock had previously closed at $10.30.
Several brokerages recently issued reports on HALO. Wells Fargo & Co. reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Canaccord Genuity reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Jefferies Group reiterated a “sell” rating and issued a $6.75 target price on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $15.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, June 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $15.68.
The firm’s market cap is $1.21 billion. The company has a 50-day moving average of $9.66 and a 200 day moving average of $9.44.
Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. The business had revenue of $33.30 million for the quarter, compared to the consensus estimate of $29.94 million. The company’s revenue was down 23.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.02 earnings per share. Equities analysts predict that Halozyme Therapeutics Inc. will post ($0.91) EPS for the current fiscal year.
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.